Phencyclidine selectively blocks the sustained voltage-dependent potassium conductance in PC12 cells.
We investigated the effects of phencyclidine (PCP), a psychotomimetic dissociative anesthetic, and several related drugs on voltage-dependent K+ currents in PC12 cells, a neuron-like clonal cell line derived from a rat pheochromocytoma. Whole-cell voltage clamp recordings demonstrated two kinetically distinct voltage-dependent outward (K+) current components in these cells: a rapidly activating and inactivating component, IA, that was selectively eliminated by 4-aminopyridine (2 mM) and a slowly activating, minimally inactivating (sustained) component, IK, that was specifically blocked by tetraethylammonium (20 mM). PCP (1-100 microM) produced a dose-dependent blockade of both IK and IA, however, at low doses the drug selectively reduced IK with little effect on IA; the IC50s for blockade of IK and IA were 4 and 25 microM, respectively. The blockade of IK was voltage-dependent so that the degree of block decreased with increasing depolarization, indicating that the blocking mechanism is likely one in which the positively charged PCP molecule is drawn into the channel pore. Several PCP related drugs also suppressed IK. Thienyl-PCP (TCP), a drug that is behaviorally more potent than PCP, partially blocked IK at low doses (31% at 1 microM), but even at high doses (25 microM) the degree of block was never as great as that produced by PCP. The optically active PCP congeners (+)-PCMP (1-(1-phenylcyclohexyl)-3-methyl-piperidine) and dexoxadrol were also potent blockers of IK. However, in contrast to the stereospecificity these compounds demonstrate in binding to high-affinity PCP receptors and in eliciting PCP-like behavioral responses, their enantiomers (-)-PCMP and levoxadrol showed similar potencies as the parent compounds in blocking IK. These results demonstrate that PCP and related drugs are powerful, selective blockers of IK in PC12 cells. The structure-activity studies indicate that this effect occurs at a site that is pharmacologically distinct from the behaviorally relevant PCP receptor. Blockade of K+ channels is unlikely to be responsible for the psychotomimetic or anti-convulsant properties of PCP, but could account for the convulsant potential of the drug.
Rogawski
M A
MA
Medical Neurology Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
Pieniek
M
M
Suzuki
S
S
ffrench-Mullen
J M
JM
D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D004148:Dioxolanes / Q000494:pharmacology; D004558:Electric Stimulation; D007473:Ion Channels / Q000187:drug effects / Q000502:physiology*; D008564:Membrane Potentials / Q000187:drug effects; D010622:Phencyclidine / Q000031:analogs & derivatives / Q000494:pharmacology*; D010673:Pheochromocytoma; D010880:Piperidines / Q000494:pharmacology; D011188:Potassium / Q000502:physiology*; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000502:physiology*
D000777:Anesthetics; D004148:Dioxolanes; D007473:Ion Channels; D010880:Piperidines; C036590:1-(1-phenylcyclohexyl)-3-methylpiperidine; C005840:dioxadrol; C579649:levoxadrol; C012058:tenocyclidine; D010622:Phencyclidine; C579650:dexoxadrol; D011188:Potassium